Calls for papers
-
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company’s Bi-Directional Breath-Powered delivery system. The study showed statistically… Read more . . .
-
Copley Scientific has announced the publication of a brochure titled “Quality Solutions for Inhaler Testing, 2015 Edition” which includes a guide for testing of novel and generic OINDPS. The brochure includes an introduction to various… Read more . . .
-
US-based Novoteris has received a $2.8 million award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for development of Thiolanox inhaled nitric oxide therapy for the treatment of bacterial lung infections in cystic fibrosis patients. The… Read more . . .
-
Inhalation Asia will co-publish a special issue of the Asian Journal of Pharmaceutical Sciences (AJPS) that will available to delegates attending the Inhalation Asia 2015 conference, September 9-11 in Shenyang, China, organizers have announced. Editors… Read more . . .
-
Alexza Pharmaceuticals has announced that it will suspend production of Adasuve inhaled loxapine for its partners Ferrer and Teva after the third quarter of 2015 “to reduce Alexza’s underutilized manufacturing capacity, overhead expenses and related… Read more . . .
-
About PPD PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in… Read more . . .
-
Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth… Read more . . .
-
Impax Specialty Pharma has received approval from the FDA to market Zomig zolmitriptan nasal spray for the treatment of migraine in patients 12-17 years of age, the company says. Impax acquired the US rights to… Read more . . .
-
Pulmatrix has issued a series of announcements regarding financing and its trading status on the NASDAQ exchange, a development deal for its PUR0200 inhaled COPD drug, and a new DPI it is developing, using its… Read more . . .
-
A study published online June 11 2015 in the American Journal of Respiratory and Critical Care Medicine showed that asthma patients over 30 years of age who were using inhaled corticosteroids experienced a greater proportion… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK